Immunohistochemical expression of ER, PR, HER2, Ki67, CK5/6 and BRCA1 in non familial breast cancer and its correlation with clinico-pathological parameters


Original Article

Author Details : Neha Bagga, Preeti Agarwal, Rajat Kumar Tuteja*, Raj Mehrotra, Kul Ranjan Singh

Volume : 8, Issue : 1, Year : 2021

Article Page : 111-119

https://doi.org/10.18231/j.ijpo.2021.022



Suggest article by email

Abstract

Background: Triple negative breast cancers (TNBC), a pathologically high grade subset of tumours has increasing prevalence in Indian population. Since their morphological features resemble with BRCA1 mutated inherited breast cancer, the present study was aimed to define the role of BRCA1 mutation in sporadic breast cancer.
Aims and Objectives: 1. To evaluate immunohistochemical expression of BRCA-1 in non familial breast cancer cases and to correlate with clinical and histopathological parameters.
Setting and Design: Prospective & Retrospective study (August 2014-August 2015). Tertiary care hospital in North Eastern India
Materials and Methods: 189 cases of suspected breast cancer cases were included in the study. ER/PR/HER2 status was evaluated of 114 cases and molecular classification along with BRCA1 expression was seen in 62 patients.
Statistical analysis: SPSS (Statistical Package for Social Sciences) Version 15.0 statistical Analysis Software. The values were represented in Number (%) and Mean±SD.
Result: 71.56% of cases belonged to Nottingham’s grade II and III. Among our groups maximum percentage were of TNBC (basal + non basal) and Her2 enriched i.e (30.6% respectively) followed by luminal B (24.2%) and luminal A (9.6%). 50% of cases in study sub population showed BRCA 1 loss.
BRCA1 expression was nuclear and cytoplasmic in both control and cases. Maximum mean BRCA1 loss was seen in basal like, followed by triple negative non basal like, her2 enriched and minimum in luminal A.
Conclusion: Large percentage of TNBC, increased BRCA1 expression loss and high grade, indicates need to fulfil the vacant space of therapeutic modality in TNBC management. PARP inhibitors, the future of therapeutic management of TNBC might also be helpful in sporadic cases of breast cancer exhibiting BRCA1 expression loss.

Keywords: BRCA1, Breast cancer, Triple negative breast cancers (TNBC).


How to cite : Bagga N , Agarwal P , Tuteja R K , Mehrotra R , Singh K R , Immunohistochemical expression of ER, PR, HER2, Ki67, CK5/6 and BRCA1 in non familial breast cancer and its correlation with clinico-pathological parameters. Indian J Pathol Oncol 2021;8(1):111-119


Copyright © 2021 by author(s) and Indian J Pathol Oncol. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)



Article History

Received : 13-12-2020

Accepted : 19-12-2020

Available online : 20-02-2021


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijpo.2021.022


Article Metrics






Article Access statistics

Viewed: 213

PDF Downloaded: 101